Figure 1.
Representative HEp-2 immunofluorescent patterns of patients with AHA. (A) ANA (1:320) of nuclear speckled pattern with few nuclear dots in an 85-year-old male patient with FVIII:C of 2.2 IU/dL and an inhibitor of 4 BU/mL. (B) ANA (1:640) of nuclear homogeneous pattern in an 86-year-old male patient with FVIII:C of 2.4 IU/dL and an inhibitor of 9 BU/mL. (C) ANA (1:640) of nucleolar pattern in an 81-year-old female patient with FVIII:C of 2.5 IU/dL and an inhibitor of 104 BU/mL. (D) Cytoplasmic reticular, “mitochondrial” pattern (without ANA) in a 52-year-old female patient with FVIII:C of 4 IU/dL and an inhibitor of 71 BU/mL. (E) Cytoplasmic discrete dots/GW body-like pattern in a 73-year-old male patient with FVIII:C of <1 IU/dL and an inhibitor of 1.5 BU/mL. (F) Combined nuclear and cytoplasmic pattern (1:160) in a 73-year-old female patient with FVIII:C of 6 IU/dL and an inhibitor of 60 BU/mL. FVIII:C, factor VIII activity.

Representative HEp-2 immunofluorescent patterns of patients with AHA. (A) ANA (1:320) of nuclear speckled pattern with few nuclear dots in an 85-year-old male patient with FVIII:C of 2.2 IU/dL and an inhibitor of 4 BU/mL. (B) ANA (1:640) of nuclear homogeneous pattern in an 86-year-old male patient with FVIII:C of 2.4 IU/dL and an inhibitor of 9 BU/mL. (C) ANA (1:640) of nucleolar pattern in an 81-year-old female patient with FVIII:C of 2.5 IU/dL and an inhibitor of 104 BU/mL. (D) Cytoplasmic reticular, “mitochondrial” pattern (without ANA) in a 52-year-old female patient with FVIII:C of 4 IU/dL and an inhibitor of 71 BU/mL. (E) Cytoplasmic discrete dots/GW body-like pattern in a 73-year-old male patient with FVIII:C of <1 IU/dL and an inhibitor of 1.5 BU/mL. (F) Combined nuclear and cytoplasmic pattern (1:160) in a 73-year-old female patient with FVIII:C of 6 IU/dL and an inhibitor of 60 BU/mL. FVIII:C, factor VIII activity.

Close Modal

or Create an Account

Close Modal
Close Modal